PUBLISHER: GlobalData | PRODUCT CODE: 1795092
PUBLISHER: GlobalData | PRODUCT CODE: 1795092
Respiratory Syncytial Virus Prophylaxis: Eight-Market Drug Forecast and Market Analysis - Update
The report provides an in-depth assessment of the RSV prophylaxis market including disease overview, epidemiology, disease management, current treatment options, unmet needs and opportunities, R&D strategies, pipeline assessment, current and future players, and market outlook.
RSV is an enveloped, single-stranded, negative-sense ribonucleic acid (RNA) orthopneumovirus belonging to the Pneumoviridae family. The most common clinical scenario for RSV is an upper respiratory tract infection (URTI), which is typically mild and self-limiting. However, RSV is the leading cause of lower respiratory tract infections (LRTIs) in infants, with a peak age of hospitalization between two to three months of age. Severe respiratory disease can manifest as bronchiolitis and pneumonia, which on rare occasions can progress to respiratory failure or death. RSV is also an important cause of hospitalizations and deaths in elderly adults.
Across the 8MM, GlobalData expects the RSV prophylaxis market to grow at a compound annual growth rate (CAGR) of 28.6% over the 2020-30 forecast period, reaching $7.2 billion by 2030. In 2020, the RSV prophylaxis market was valued at $582M, with all sales attributable to AstraZeneca/AbbVie's Synagis (palivizumab), a monoclonal antibody (mAb) indicated for use in high-risk infants. The RSV prophylaxis market has undergone significant growth and diversification in the following years owing to the launch of two more mAbs, AstraZeneca/Sanofi's Beyfortus (nirsevimab) and Merck &Co's Enflonsia (clesrovimab), as well as the first RSV vaccines, GSK's Arexvy, Pfizer's Abrysvo, and Moderna's mRESVIA. Five vaccines in late-stage development will also drive market growth. These are GSK's GSK-3888550A, AdVaccine's BARS-13, and Sanofi's SP-0256, SP-0274, and SP-0125.
Key Highlights
- Report deliverables include a Pdf report and an Excel-based forecast model
- Forecast includes the 8 major markets (8MM)
- Forecast covers the period 2020-2030
Scope
- Overview of RSV including etiology, pathophysiology and epidemiology.
- Key topics covered include current market landscape, strategic competitor assessment, unmet needs and opportunities, R&D trends, pipeline assessment, and current and future players.
- RSV prophylaxis market outlook from 2020-2030, including annual cost of therapy per patient, and total sales revenues per product for each of the 8MM.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and identify the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the 8MM RSV prophylaxis market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 8MM RSV prophylaxis market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Table of Contents
1 Respiratory Syncytial Virus Prophylaxis: Executive Summary - Updated July 2025, based on events up to July 2025
- 1.1 Summary of changes
- 1.2 RSV prophylaxis market to reach $7.2 billion by 2030
- 1.3 Unmet needs remain despite influx of novel products
- 1.4 Prophylactic options to continue to diversify due to strength of late-stage pipeline
- 1.5 What do physicians think?
2 Introduction - Updated July 2025, based on events up to July 2025
- 2.1 Catalyst
- 2.2 Related reports
- 2.3 Upcoming reports
3 Disease Overview - Updated Nov 2024, based on events up to Nov 2024
- 3.1 Etiology and pathophysiology
- 3.1.1 Etiology
- 3.1.2 Pathophysiology
4 Epidemiology - Updated Aug 2021, based on events up to Aug 2021
- 4.1 Disease background
- 4.1.1 Risk factors and comorbidities
- 4.2 Global and historical trends
- 4.3 Forecast methodology
- 4.3.1 Sources
- 4.3.2 Forecast assumptions and methods
- 4.4 Epidemiological forecast for RSV prophylactic population (2020-30)
- 4.4.1 Number of preterm births by gestational age
- 4.4.2 Preterm infants with CLD
- 4.4.3 Number of live births with hemodynamically significant heart disease and congenital lung disease
- 4.4.4 Diagnosed prevalent cases of DMD
- 4.4.5 Diagnosed prevalent cases of SMA
- 4.4.6 Number of third-trimester pregnant women
- 4.4.7 Number of adults living in nursing homes/long-term care institutions
- 4.5 Discussion
- 4.5.1 Epidemiological forecast insight
- 4.5.2 Limitations of the analysis
- 4.5.3 Strengths of the analysis
5 Disease Management - Updated July 2025, based on events up to July 2025
- 5.1 Diagnosis
- 5.2 Prophylaxis
- 5.3 Treatment
- 5.4 KOL insights on disease management
6 Current Treatment Options - Updated July 2025, based on events up to July 2025
- 6.1 Overview
7 Unmet Needs and Opportunity Assessment - Updated July 2025, based on events up to July 2025
- 7.1 Overview
- 7.2 Increased diagnostic testing
- 7.3 Increased research and awareness of long-term sequelae
- 7.4 Combination vaccines
- 7.5 Prophylaxis for immunocompromised patients
8 R&D Strategies - Updated July 2025, based on events up to July 2025
- 8.1 Overview
- 8.1.1 Leveraging novel vaccine technologies and strategies
- 8.1.2 Development of prophylactic antibodies with improved dosing and efficacy
- 8.2 Clinical trial design
- 8.2.1 Clinical trial design for RSV prophylactics for maternal immunization
- 8.2.2 Clinical trial design for RSV prophylactics for pediatric immunization
- 8.2.3 Clinical trial design for RSV prophylactics for adult immunization
9 Pipeline Assessment - Updated July 2025, based on events up to July 2025
- 9.1 Overview
- 9.2 Promising drugs in clinical development
10 Pipeline Valuation Analysis - Updated July 2025, based on events up to July 2025
- 10.1 Overview
- 10.2 Competitive assessment
- 10.2.1 Pipeline maternal vaccine products
- 10.2.2 Pipeline vaccine products for adults
11 Current and Future Players - Updated July 2025, based on events up to July 2025
- 11.1 Overview
- 11.2 Deal-making trends
12 Market Outlook - Updated July 2025, based on events up to July 2025
- 12.1 Global markets
- 12.1.1 Forecast
- 12.1.2 Drivers and barriers
- 12.2 US
- 12.2.1 Forecast
- 12.2.2 Key events
- 12.2.3 Drivers and barriers
- 12.3 5EU
- 12.3.1 Forecast
- 12.3.2 Key events
- 12.3.3 Drivers and barriers
- 12.4 Japan
- 12.4.1 Forecast
- 12.4.2 Key events
- 12.4.3 Drivers and barriers
- 12.5 Australia
- 12.5.1 Forecast
- 12.5.2 Key events
- 12.5.3 Drivers and barriers
13 Appendix
- 13.1 Bibliography
- 13.2 Abbreviations
- 13.3 Methodology
- 13.3.1 Forecasting methodology
- 13.4 Primary Research - KOLs interviewed for this report
- 13.5 Primary research - prescriber survey
- 13.6 About the Authors
- 13.6.1 Analyst
- 13.6.2 Therapy Area Director
- 13.6.3 Epidemiologist
- 13.6.4 Epidemiology Reviewers
- 13.6.5 Vice President of Disease Intelligence and Epidemiology
- 13.6.6 Global Head of Pharma Research, Analysis and Competitive Intelligence
- About GlobalData
- Contact Us
